{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T22:52:07Z","timestamp":1787698327288,"version":"build-2784847793"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973334"],"award-info":[{"award-number":["81973334"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82003769"],"award-info":[{"award-number":["82003769"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473932"],"award-info":[{"award-number":["82473932"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81773702"],"award-info":[{"award-number":["81773702"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021ZD0204004"],"award-info":[{"award-number":["2021ZD0204004"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2021YFE0206000"],"award-info":[{"award-number":["2021YFE0206000"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.neuropharm.2025.110374","type":"journal-article","created":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T19:14:47Z","timestamp":1739992487000},"page":"110374","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Serum amyloid A drive microglia shift to a resolving phenotype through Nrf2"],"prefix":"10.1016","volume":"270","author":[{"given":"Qi","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tao","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7458-2566","authenticated-orcid":false,"given":"Xuechu","family":"Zhen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qijun","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6727-6034","authenticated-orcid":false,"given":"Gufang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2025.110374_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.arr.2023.102119","article-title":"Evaluation and targeting of amyloid precursor protein (APP)\/amyloid beta (Abeta) axis in amyloidogenic and non-amyloidogenic pathways: a time outside the tunnel","volume":"92","author":"Al-Kuraishy","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"10.1016\/j.neuropharm.2025.110374_bib2","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s13098-023-01082-1","article-title":"The potential role of human islet amyloid polypeptide in type 2 diabetes mellitus and Alzheimer's diseases","volume":"15","author":"Alrouji","year":"2023","journal-title":"Diabetol. Metab. Syndr."},{"key":"10.1016\/j.neuropharm.2025.110374_bib3","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson's disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.neuropharm.2025.110374_bib4","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/acps.12730","article-title":"The acute-phase mediator serum amyloid A is associated with symptoms of depression and fatigue","volume":"135","author":"Bryleva","year":"2017","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.neuropharm.2025.110374_bib5","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/med.21925","article-title":"KEAP1-NRF2 protein-protein interaction inhibitors: design, pharmacological properties and therapeutic potential","volume":"43","author":"Crisman","year":"2023","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.neuropharm.2025.110374_bib6","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1111\/jnc.12675","article-title":"Insights into the physiological function of the beta-amyloid precursor protein: beyond Alzheimer's disease","volume":"129","author":"Dawkins","year":"2014","journal-title":"J. Neurochem."},{"key":"10.1016\/j.neuropharm.2025.110374_bib7","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1016\/j.immuni.2022.09.005","article-title":"Differential plasticity and fate of brain-resident and recruited macrophages during the onset and resolution of neuroinflammation","volume":"55","author":"De Vlaminck","year":"2022","journal-title":"Immunity"},{"key":"10.1016\/j.neuropharm.2025.110374_bib8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.cytogfr.2021.01.007","article-title":"Molecular regulation of autophagy in a pro-inflammatory tumour microenvironment: new insight into the role of serum amyloid A","volume":"59","author":"du Plessis","year":"2021","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.neuropharm.2025.110374_bib9","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s12974-018-1205-6","article-title":"Serum amyloid A primes microglia for ATP-dependent interleukin-1beta release","volume":"15","author":"Facci","year":"2018","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2025.110374_bib10","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.bbi.2016.10.018","article-title":"Clk1 deficiency promotes neuroinflammation and subsequent dopaminergic cell death through regulation of microglial metabolic reprogramming","volume":"60","author":"Gu","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.neuropharm.2025.110374_bib11","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-018-31517-z","article-title":"Cerebrospinal fluid concentrations of inflammatory markers in Parkinson's disease and atypical parkinsonian disorders","volume":"8","author":"Hall","year":"2018","journal-title":"Sci. Rep."},{"key":"10.1016\/j.neuropharm.2025.110374_bib12","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1007\/s00401-021-02268-5","article-title":"Periphery and brain, innate and adaptive immunity in Parkinson's disease","volume":"141","author":"Harms","year":"2021","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.neuropharm.2025.110374_bib13","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3389\/fnins.2019.00013","article-title":"Serum amyloid alpha is downregulated in peripheral tissues of Parkinson's disease patients","volume":"13","author":"Kurvits","year":"2019","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110374_bib14","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1080\/15548627.2020.1712108","article-title":"SQSTM1\/p62 activates NFE2L2\/NRF2 via ULK1-mediated autophagic KEAP1 degradation and protects mouse liver from lipotoxicity","volume":"16","author":"Lee","year":"2020","journal-title":"Autophagy"},{"key":"10.1016\/j.neuropharm.2025.110374_bib15","doi-asserted-by":"crossref","DOI":"10.1172\/JCI167835","article-title":"Serum amyloid A expression in liver promotes synovial macrophage activation and chronic arthritis via NFAT5","volume":"134","author":"Li","year":"2024","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.neuropharm.2025.110374_bib16","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/S0304-3940(97)00196-1","article-title":"Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain","volume":"225","author":"Liang","year":"1997","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110374_bib17","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12974-016-0493-y","article-title":"Suppression of LPS-induced tau hyperphosphorylation by serum amyloid A","volume":"13","author":"Liu","year":"2016","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.neuropharm.2025.110374_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.neulet.2020.135352","article-title":"Serum amyloid A-induced blood-brain barrier dysfunction associated with decreased claudin-5 expression in rat brain endothelial cells and its inhibition by high-density lipoprotein in vitro","volume":"738","author":"Matsumoto","year":"2020","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2025.110374_bib19","doi-asserted-by":"crossref","first-page":"3617","DOI":"10.1111\/bph.15193","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"177","author":"Percie du Sert","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110374_bib20","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.4049\/jimmunol.1402164","article-title":"Ex vivo and in vitro effect of serum amyloid a in the induction of macrophage M2 markers and efferocytosis of apoptotic neutrophils","volume":"194","author":"Sun","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.neuropharm.2025.110374_bib21","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1002\/eji.201344310","article-title":"Serum amyloid A induces interleukin-33 expression through an IRF7-dependent pathway","volume":"44","author":"Sun","year":"2014","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.neuropharm.2025.110374_bib22","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.1161\/ATVBAHA.118.310979","article-title":"Serum amyloid A is an exchangeable apolipoprotein","volume":"38","author":"Wilson","year":"2018","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.neuropharm.2025.110374_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2020.577466","article-title":"Serum amyloid A level correlates with T2 lesion volume and cortical volume in patients with multiple sclerosis","volume":"351","author":"Yokote","year":"2021","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.neuropharm.2025.110374_bib24","doi-asserted-by":"crossref","first-page":"9465","DOI":"10.1523\/JNEUROSCI.0801-19.2019","article-title":"Serum amyloid A-mediated inflammasome activation of microglial cells in cerebral ischemia","volume":"39","author":"Yu","year":"2019","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110374_bib25","doi-asserted-by":"crossref","first-page":"133","DOI":"10.3233\/JAD-130818","article-title":"Serum amyloid a differentially activates microglia and astrocytes via the PI3K pathway","volume":"38","author":"Yu","year":"2014","journal-title":"J Alzheimers Dis"},{"key":"10.1016\/j.neuropharm.2025.110374_bib26","first-page":"171","article-title":"Neuroinflammatory biomarkers for traumatic brain injury diagnosis and prognosis: a TRACK-TBI pilot study","volume":"4","author":"Yue","year":"2023","journal-title":"Neurotrauma Rep."},{"key":"10.1016\/j.neuropharm.2025.110374_bib27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.7150\/thno.77088","article-title":"Sigma-1 receptor-regulated efferocytosis by infiltrating circulating macrophages\/microglial cells protects against neuronal impairments and promotes functional recovery in cerebral ischemic stroke","volume":"13","author":"Zhang","year":"2023","journal-title":"Theranostics"},{"key":"10.1016\/j.neuropharm.2025.110374_bib28","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/bs.acc.2019.01.002","article-title":"Acute phase reactant serum amyloid A in inflammation and other diseases","volume":"90","author":"Zhang","year":"2019","journal-title":"Adv. Clin. Chem."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825000802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825000802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T09:07:28Z","timestamp":1777453648000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825000802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":28,"alternative-id":["S0028390825000802"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110374","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum amyloid A drive microglia shift to a resolving phenotype through Nrf2","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110374","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110374"}}